NCT07052877招募中不适用
Investigating Glioblastoma PSMA Expression by Utilizing Anti-VEGF and Its Effect on PSMA PET Scan Avidity
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Changes in PSMA PET metabolic tumour volume (MTV) before and after bevacizumab administration.
研究概览
简要总结
This trial is a single arm study for patients receiving bevacizumab for IDH-wildtype glioblastoma. Patients receiving bevacizumab (an anti-VEGF therapy) will receive PSMA scans to investigate the role of PSMA expression in glioblastoma and its relationship to VEGF expression.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •> 18 year of age
- •Able to provide informed consent for the study
- •Minimum of 1 month from completion of radiotherapy with clinical or radiography evidence suggesting residual tumour
- •Confirmed glioblastoma IDH1/2 wildtype (WHO2021)
- •For bevacizumab treatment as per treating physician
- •Able to comply with trial requirements
排除标准
- •No major organ impairment that would likely lead to unacceptable toxicities- eg significant cardiac, hepatic, renal or haematologic dysfunction (based on clinician assessment)
- •Any contraindication to bevacizumab, MRI gadolinium contrast or 68Ga-PSMA-617 radioisotope
- •Any implant, foreign body, 3T MRI incompatible device or other contraindication to MRI imaging
- •Does not fulfill PBS requirements for bevacizumab
- •Women lactating, pregnant or of child baring potential who are not willing to avoid pregnancy during the study
研究组 & 干预措施
Patients with glioblastoma receiving Bevacizumab as part of their standard of care
干预措施: PSMA PET/CT scan (Diagnostic Test)
结局指标
主要结局
Changes in PSMA PET metabolic tumour volume (MTV) before and after bevacizumab administration.
时间窗: Prior to first administration of bevacizumab to 6 weeks after.
次要结局
未报告次要终点
研究者
Alexander Yuile
Principal Investigator
Royal North Shore Hospital
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study of Subcutaneous Bevacizumab in Relapsed / Progressive GlioblastomaGlioblastomaNCT02157103Emory University3
已完成
1 期
Suberoylanilide Hydroxamic Acid (SAHA), Bevacizumab, Daily Temozolomide for Recurrent Malignant GliomasGlioblastomaBrain TumorNCT00939991Katy Peters48
已完成
2 期
BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM)GliosarcomaGBMGlioblastoma MultiformeNCT01856933Heinrich Elinzano, MD6
已完成
2 期
Bevacizumab, Temozolomide and Hypofractionated Radiotherapy for Patients With Newly Diagnosed Malignant GliomaBrain CancerMalignant GliomaNCT00782756Memorial Sloan Kettering Cancer Center40
招募中
2 期
An Investigational Scan (Ga-68 PSMA-11 PET/CT) for Detection of Disease Recurrence or Progression in Patients With GliomaWHO Grade 3 GliomaWHO Grade 4 GliomaNCT06444412Mayo Clinic25